Concurrent radiation with irinotecan and carboplatin in intermediate‐ and high‐risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study

Irinotecan is highly active against rhabdomyosarcoma (RMS), yet its tolerability and efficacy in combination with radiation is unknown. We examined local control and toxicities in RMS patients treated with radiotherapy (RT) in combination with radiosensitizing agents irinotecan + carboplatin (I + C).

[1]  M. Fukuoka,et al.  Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer , 1999, British Journal of Cancer.

[2]  J. Meza,et al.  Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Gerald,et al.  Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience , 2002, Journal of pediatric hematology/oncology.

[5]  P. Houghton,et al.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors , 2004, Cancer Chemotherapy and Pharmacology.

[6]  K. McHugh,et al.  Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma. , 2007, European journal of cancer.

[7]  M. Bernstein,et al.  Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.

[8]  J. Meza,et al.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. , 2001, International journal of radiation oncology, biology, physics.

[9]  A. Angiolillo,et al.  Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors , 2009, Cancer.

[10]  M. Haider,et al.  Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer , 2010, Cancer.

[11]  M. Carli,et al.  Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine. , 1996, European journal of cancer.

[12]  P. Sorensen,et al.  The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols , 2001, Sarcoma.

[13]  Karen Morano,et al.  Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[14]  D. Kraus,et al.  Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. , 2004, International journal of radiation oncology, biology, physics.

[15]  J. Healey,et al.  Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era. , 2006, International journal of radiation oncology, biology, physics.

[16]  M. Bernstein,et al.  A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  P. Houghton,et al.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. , 1993, Cancer research.

[18]  P. Houghton,et al.  Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Choy,et al.  Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. , 2000, Oncology.

[20]  W. Meyer,et al.  Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.